Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lurdes Zamora

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Cancer|July 22, 2015
Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocolsJordi Ribera, Mireia Morgades, Lurdes Zamora, et al.
Nature Communications|October 19, 2021
Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesisJeannine Diesch, Marguerite-Marie Le Pannérer, René Winkler, et al.
British Journal of Haematology|March 12, 2024
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective studyAleix Noguera-Castells, Ignacio Campillo-Marcos, Veronica Davalos, et al.
Cytometry. Part B, Clinical Cytometry|June 13, 2020
FMOD expression in whole blood aids in distinguishing between chronic lymphocytic leukemia and other leukemic lymphoproliferative disorders. A pilot studyMarc Sorigue, Jordi Junca, Christelle Ferra, et al.
Journal of Clinical Medicine|February 10, 2024
e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular ResponseSílvia Marcé, Aleix Méndez, Blanca Xicoy, et al.
Hematological Oncology|May 4, 2016
Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approachJosep F Nomdedéu, Eulalia Puigdecanet, Elena Bussaglia, et al.
Oncotarget|April 30, 2016
Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysisFernando Ramos, Cristina Robledo, Francisco Miguel Izquierdo-García, et al.
Blood Cancer Journal|January 11, 2025
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM GroupGuadalupe Oñate, Ana Garrido, Montserrat Arnan, et al.
British Journal of Haematology|June 9, 2020
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual diseaseAlex Bataller, Guadalupe Oñate, Marina Diaz-Beyá, et al.
Journal of Clinical Medicine|July 24, 2021
Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with ImatinibSílvia Marcé, Blanca Xicoy, Olga García, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Cancer|July 22, 2015
Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocolsJordi Ribera, Mireia Morgades, Lurdes Zamora, et al.
Nature Communications|October 19, 2021
Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesisJeannine Diesch, Marguerite-Marie Le Pannérer, René Winkler, et al.
British Journal of Haematology|March 12, 2024
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective studyAleix Noguera-Castells, Ignacio Campillo-Marcos, Veronica Davalos, et al.
Cytometry. Part B, Clinical Cytometry|June 13, 2020
FMOD expression in whole blood aids in distinguishing between chronic lymphocytic leukemia and other leukemic lymphoproliferative disorders. A pilot studyMarc Sorigue, Jordi Junca, Christelle Ferra, et al.
Journal of Clinical Medicine|February 10, 2024
e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular ResponseSílvia Marcé, Aleix Méndez, Blanca Xicoy, et al.
Hematological Oncology|May 4, 2016
Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approachJosep F Nomdedéu, Eulalia Puigdecanet, Elena Bussaglia, et al.
Oncotarget|April 30, 2016
Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysisFernando Ramos, Cristina Robledo, Francisco Miguel Izquierdo-García, et al.
Blood Cancer Journal|January 11, 2025
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM GroupGuadalupe Oñate, Ana Garrido, Montserrat Arnan, et al.
British Journal of Haematology|June 9, 2020
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual diseaseAlex Bataller, Guadalupe Oñate, Marina Diaz-Beyá, et al.
Journal of Clinical Medicine|July 24, 2021
Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with ImatinibSílvia Marcé, Blanca Xicoy, Olga García, et al.
Pageof 7